The global Small Molecule Drug CDMO market size is predicted to grow from US$ 31980 million in 2025 to US$ 45680 million in 2031; it is expected to grow at a CAGR of 6.1% from 2025 to 2031.

A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.

The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

ReportPrime' newest research report, the “Small Molecule Drug CDMO Industry Forecast” looks at past sales and reviews total world Small Molecule Drug CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Small Molecule Drug CDMO sales for 2025 through 2031.

This Insight Report provides a comprehensive analysis of the global Small Molecule Drug CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Small Molecule Drug CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Small Molecule Drug CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Small Molecule Drug CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Small Molecule Drug CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Small Molecule Drug CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type

• FDF CDMO
• Packaging CDMO
• Clinical CDMO

Segmentation by Application

• Pharmaceutical Company
• Biotechnology Company
• Other

Market by Region

• Americas
• APAC
• Europe
• Middle East & Africa

Company Coverage

• Lonza
• Catalent
• Thermo Fisher Scientific
• Samsung Biologics
• Fareva
• WuXi AppTech
• WuXi Biologics
• Siegfried
• FUJIFILM Diosynth Biotechnologies
• Asymchem
• Pfizer CentreOne
• Delpharm
• Recipharm
• AGC Pharma Chemicals
• Boehringer Ingelheim
• Vetter
• Curia
• Aenova
• Porton

Key Questions Addressed in this Report